Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial
Background Endotype classification may guide immunomodulatory management of patients with bacterial and viral sepsis. We aimed to identify immune endotypes and transitions associated with response to anakinra (human interleukin 1 receptor antagonist) in participants in the SAVE-MORE trial. Methods Adult patients hospitalized with radiological findings of PCR-confirmed severe pneumonia caused by SARS-CoV-2 and plasma-soluble urokinase plasminogen activator receptor levels of ≥ 6 ng/ml in the SAVE-MORE trial (NCT04680949) were characterized at baseline and days 4 and 7 of treatment using a previously defined 33-messenger RNA classifier to assign an immunological endotype in blood. Endpoints were changes in endotypes and progression to severe respiratory failure (SRF) associated with anakinra treatment. Results At baseline, 23.2% of 393 patients were designated as inflammopathic, 41.1% as adaptive, and 35.7% as coagulopathic. Only 23.9% were designated as the same endotype at days 4 and 7 compared to baseline, while all other patients transitioned between endotypes. Anakinra-treated patients were more likely to remain in the adaptive endotype during 7-day treatment (24.4% vs. 9.9%; p < 0.001). Anakinra also protected patients with coagulopathic endotype at day 7 against SRF compared to placebo (27.8% vs. 55.9%; p = 0.013). Conclusion We identify an association between endotypes defined using blood transcriptome and anakinra therapy for COVID-19 pneumonia, with anakinra-treated patients shifting toward endotypes associated with a better outcome, mainly the adaptive endotype. Trial registration ClinicalTrials.gov, NCT04680949, December 23, 2020..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:28 |
|---|---|
| Enthalten in: |
Critical care - 28(2024), 1 vom: 12. März |
| Sprache: |
Englisch |
|---|
| Links: |
Volltext [kostenfrei] |
|---|
| BKL: | |
|---|---|
| Themen: |
| Anmerkungen: |
© The Author(s) 2024 |
|---|
| doi: |
10.1186/s13054-024-04852-z |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
SPR055121233 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR055121233 | ||
| 003 | DE-627 | ||
| 005 | 20240314064715.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240314s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s13054-024-04852-z |2 doi | |
| 035 | |a (DE-627)SPR055121233 | ||
| 035 | |a (SPR)s13054-024-04852-z-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 44.00 |2 bkl | ||
| 100 | 1 | |a Kyriazopoulou, Evdoxia |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Transitions of blood immune endotypes and improved outcome by anakinra in COVID-19 pneumonia: an analysis of the SAVE-MORE randomized controlled trial |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a © The Author(s) 2024 | ||
| 520 | |a Background Endotype classification may guide immunomodulatory management of patients with bacterial and viral sepsis. We aimed to identify immune endotypes and transitions associated with response to anakinra (human interleukin 1 receptor antagonist) in participants in the SAVE-MORE trial. Methods Adult patients hospitalized with radiological findings of PCR-confirmed severe pneumonia caused by SARS-CoV-2 and plasma-soluble urokinase plasminogen activator receptor levels of ≥ 6 ng/ml in the SAVE-MORE trial (NCT04680949) were characterized at baseline and days 4 and 7 of treatment using a previously defined 33-messenger RNA classifier to assign an immunological endotype in blood. Endpoints were changes in endotypes and progression to severe respiratory failure (SRF) associated with anakinra treatment. Results At baseline, 23.2% of 393 patients were designated as inflammopathic, 41.1% as adaptive, and 35.7% as coagulopathic. Only 23.9% were designated as the same endotype at days 4 and 7 compared to baseline, while all other patients transitioned between endotypes. Anakinra-treated patients were more likely to remain in the adaptive endotype during 7-day treatment (24.4% vs. 9.9%; p < 0.001). Anakinra also protected patients with coagulopathic endotype at day 7 against SRF compared to placebo (27.8% vs. 55.9%; p = 0.013). Conclusion We identify an association between endotypes defined using blood transcriptome and anakinra therapy for COVID-19 pneumonia, with anakinra-treated patients shifting toward endotypes associated with a better outcome, mainly the adaptive endotype. Trial registration ClinicalTrials.gov, NCT04680949, December 23, 2020. | ||
| 650 | 4 | |a Endotypes |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Anakinra |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a COVID-19 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Viral sepsis |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Hasin-Brumshtein, Yehudit |4 aut | |
| 700 | 1 | |a Midic, Uros |4 aut | |
| 700 | 1 | |a Poulakou, Garyfallia |4 aut | |
| 700 | 1 | |a Milionis, Haralampos |4 aut | |
| 700 | 1 | |a Metallidis, Simeon |4 aut | |
| 700 | 1 | |a Astriti, Myrto |4 aut | |
| 700 | 1 | |a Fragkou, Archontoula |4 aut | |
| 700 | 1 | |a Rapti, Aggeliki |4 aut | |
| 700 | 1 | |a Taddei, Eleonora |4 aut | |
| 700 | 1 | |a Kalomenidis, Ioannis |4 aut | |
| 700 | 1 | |a Chrysos, Georgios |4 aut | |
| 700 | 1 | |a Angheben, Andrea |4 aut | |
| 700 | 1 | |a Kainis, Ilias |4 aut | |
| 700 | 1 | |a Alexiou, Zoi |4 aut | |
| 700 | 1 | |a Castelli, Francesco |4 aut | |
| 700 | 1 | |a Serino, Francesco Saverio |4 aut | |
| 700 | 1 | |a Bakakos, Petros |4 aut | |
| 700 | 1 | |a Nicastri, Emanuele |4 aut | |
| 700 | 1 | |a Tzavara, Vasiliki |4 aut | |
| 700 | 1 | |a Ioannou, Sofia |4 aut | |
| 700 | 1 | |a Dagna, Lorenzo |4 aut | |
| 700 | 1 | |a Dimakou, Katerina |4 aut | |
| 700 | 1 | |a Tzatzagou, Glykeria |4 aut | |
| 700 | 1 | |a Chini, Maria |4 aut | |
| 700 | 1 | |a Bassetti, Matteo |4 aut | |
| 700 | 1 | |a Kotsis, Vasileios |4 aut | |
| 700 | 1 | |a Tsoukalas, Dionysios G. |4 aut | |
| 700 | 1 | |a Selmi, Carlo |4 aut | |
| 700 | 1 | |a Konstantinou, Alexandra |4 aut | |
| 700 | 1 | |a Samarkos, Michael |4 aut | |
| 700 | 1 | |a Doumas, Michael |4 aut | |
| 700 | 1 | |a Masgala, Aikaterini |4 aut | |
| 700 | 1 | |a Pagkratis, Konstantinos |4 aut | |
| 700 | 1 | |a Argyraki, Aikaterini |4 aut | |
| 700 | 1 | |a Akinosoglou, Karolina |4 aut | |
| 700 | 1 | |a Symbardi, Styliani |4 aut | |
| 700 | 1 | |a Netea, Mihai G. |4 aut | |
| 700 | 1 | |a Panagopoulos, Periklis |4 aut | |
| 700 | 1 | |a Dalekos, George N. |4 aut | |
| 700 | 1 | |a Liesenfeld, Oliver |4 aut | |
| 700 | 1 | |a Sweeney, Timothy E. |4 aut | |
| 700 | 1 | |a Khatri, Purvesh |4 aut | |
| 700 | 1 | |a Giamarellos-Bourboulis, Evangelos J. |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Critical care |d BioMed Central, 1997 |g 28(2024), 1 vom: 12. März |w (DE-627)SPR029726166 |w (DE-600)2051256-9 |x 1364-8535 |7 nnns |
| 773 | 1 | 8 | |g volume:28 |g year:2024 |g number:1 |g day:12 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s13054-024-04852-z |z kostenfrei |3 Volltext |
| 912 | |a GBV_SPRINGER | ||
| 912 | |a SSG-OLC-PHA | ||
| 936 | b | k | |a 44.00 |q VZ |
| 951 | |a AR | ||
| 952 | |d 28 |j 2024 |e 1 |b 12 |c 03 | ||